These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 15127424)

  • 61. Estimating a cost-effectiveness threshold for the Spanish NHS.
    Vallejo-Torres L; GarcΓ­a-Lorenzo B; Serrano-Aguilar P
    Health Econ; 2018 Apr; 27(4):746-761. PubMed ID: 29282798
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The social value of a QALY: raising the bar or barring the raise?
    Donaldson C; Baker R; Mason H; Jones-Lee M; Lancsar E; Wildman J; Bateman I; Loomes G; Robinson A; Sugden R; Prades JL; Ryan M; Shackley P; Smith R
    BMC Health Serv Res; 2011 Jan; 11():8. PubMed ID: 21223540
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Is the aim of the English health care system to maximize QALYs?
    Shah K; Praet C; Devlin N; Sussex J; Appleby J; Parkin D
    J Health Serv Res Policy; 2012 Jul; 17(3):157-63. PubMed ID: 22767891
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England.
    Cherla A; Renwick M; Jha A; Mossialos E
    EClinicalMedicine; 2020 Dec; 29-30():100625. PubMed ID: 33437948
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Crossing the line: NICE's value for money threshold.
    Appleby J
    BMJ; 2016 Mar; 352():i1336. PubMed ID: 26960807
    [No Abstract]   [Full Text] [Related]  

  • 66. Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.
    McCaffrey N; Agar M; Harlum J; Karnon J; Currow D; Eckermann S
    PLoS One; 2015; 10(3):e0115544. PubMed ID: 25751629
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.
    Claxton K; Sculpher M; Culyer A; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J
    Health Econ; 2006 Jan; 15(1):1-4. PubMed ID: 16365910
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG.
    Gandjour A
    BMC Health Serv Res; 2020 Apr; 20(1):343. PubMed ID: 32321496
    [TBL] [Abstract][Full Text] [Related]  

  • 69. NICE methodological guidelines and decision making in the National Health Service in England and Wales.
    Gafni A; Birch S; ;
    Pharmacoeconomics; 2003; 21(3):149-57. PubMed ID: 12558466
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Precision QALYs, Precisely Unjust.
    Fleck LM
    Camb Q Healthc Ethics; 2019 Jul; 28(3):439-449. PubMed ID: 31298190
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An analysis of NICE's 'restricted' (or 'optimized') decisions.
    O'Neill P; Devlin NJ
    Pharmacoeconomics; 2010; 28(11):987-93. PubMed ID: 20936882
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The value of implementation and the value of information: combined and uneven development.
    Fenwick E; Claxton K; Sculpher M
    Med Decis Making; 2008; 28(1):21-32. PubMed ID: 18263559
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness.
    Svensson M; Nilsson FO; Arnberg K
    Pharmacoeconomics; 2015 Nov; 33(11):1229-36. PubMed ID: 26093889
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The appropriate role of cost-effectiveness in determining device coverage: a case study of drug-eluting stents.
    Firth BG; Cooper LM; Fearn S
    Health Aff (Millwood); 2008; 27(6):1577-86. PubMed ID: 18997214
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Decade of Health Innovation: The Impact of New Medicines on Patient Health and the Implications for NICE's Size of Benefit Multiplier.
    Shafrin J; Quddus S; Marin M; Scanlon D
    Value Health; 2023 Oct; 26(10):1435-1439. PubMed ID: 37391164
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost effectiveness and the role of the National Institute of Health and Care Excellence (NICE) in interventional radiology.
    Maudgil DD
    Clin Radiol; 2021 Mar; 76(3):185-192. PubMed ID: 33081990
    [TBL] [Abstract][Full Text] [Related]  

  • 77. NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.
    Brown P; Calnan M
    Med Health Care Philos; 2013 May; 16(2):281-93. PubMed ID: 22198480
    [TBL] [Abstract][Full Text] [Related]  

  • 78. NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
    O'Mahony JF; Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):139-146. PubMed ID: 33462758
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.